For decades, psoriasis has been treated as a condition of the skin — visible, manageable, local. Yet the inflammation driving those familiar plaques does not confine itself to the surface; it moves through blood vessels, stresses the heart, and quietly elevates the risk of cardiovascular events. As clinical evidence solidifies this understanding, pharmacists — trusted, accessible, and positioned at the crossroads of patient care — are being called to widen their counsel beyond the prescription pad and into the fuller story of what it means to live with a whole-body inflammatory disease.
Psoriasis linked to cardiovascular risk as systemic inflammatory disease
Cobertura Relacionada
An SUV driver under the influence of drugs has been charged with murder after slamming into a Los Angeles city bus, kill…
BBC News · Sep 18 NHS trust admits 20 women had breasts removed unnecessarily in cancer care scandalAn NHS trust in County Durham has admitted that 20 women underwent unnecessary mastectomies during cancer treatment, wit…
News-Medical · Sep 18 Eight-weekly HIV injections outperform daily tablets in young people, UCL trial showsA UCL-led trial across Africa found that eight-weekly HIV injections are significantly more effective than daily tablets…
News-Medical · Sep 18 CGM Devices Reveal Glucose Patterns Linked to Heart Disease Risk in Non-DiabeticsBoston University researchers found that continuous glucose monitoring patterns in non-diabetic adults correlate with ca…
Viés e Enquadramento
Não há dados de análise detalhada para esta lente. Tente executar as lentes novamente no painel de administração.
Impacto Geopolítico
Medical journal article on psoriasis-cardiovascular link has no geopolitical implications; this is a clinical/pharmaceutical publication without international relations content.
Lente Econômica
Psoriasis recognized as systemic inflammatory disease with cardiovascular implications, expanding pharmaceutical care scope and creating demand for integrated treatment approaches.
Patients with psoriasis face expanded healthcare costs and complexity; require integrated cardiovascular monitoring and preventive treatments. Increased out-of-pocket expenses for comprehensive care and specialist consultations.
Potential regulatory expansion of pharmacist scope of practice to include cardiovascular risk assessment for psoriasis patients. May drive reimbursement policy changes to cover integrated care models. Possible guidelines updates requiring cardiovascular screening protocols for psoriasis treatment.